Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections. Key pipeline programs include AP-SA02, a multi-phage cocktail for Staphylococcus aureus bacteremia, and candidates targeting Pseudomonas aeruginosa. The company conducts its own cGMP manufacturing to produce these biologic therapies.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -6.5 | — |
| Q2 2025 | 0 | — | -16.3 | — |
| Q3 2025 | 0 | — | -26.7 | — |
| Q4 2025 | 0 | — | -124.3 | — |
| Q1 2026 | 0 | — | -115.3 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE American: GoldMining Inc. (GLDG), Equinox Gold Corp. (EQX), Sprott Physical Silver Trust (PSLV), B2Gold Corp. (BTG), Uranium Energy Corp. (UEC), Grupo Simec, S.A.B. de C.V. (SIM)